Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial

► Intravenous zoledronate, 5 mg, reduces fracture risk, but the optimal dosing regimen is uncertain. ► A 5 mg dose of zoledronate stably reduced bone turnover and increased bone density for 5 years in postmenopausal women. ► Investigation of the anti-fracture efficacy of dosing intervals of zoledronate of up to 5 years is justified.